[Pubmed] Management of autoimmune conditions associated with thymic epithelial tumors
Posté : 22 sept. 2025 12:00
J Thorac Oncol. 2025 Sep 20:S1556-0864(25)01063-9. doi: 10.1016/j.jtho.2025.09.013. Online ahead of print.
ABSTRACT
Thymic epithelial tumors are associated with diverse autoimmune manifestations, with 30-50% of patients developing at least one autoimmune condition. The pathogenesis involves thymic dysfunction leading to impaired T-cell development and self-tolerance. Myasthenia gravis is the most common, followed by less frequent but notable conditions including pure red cell aplasia, Good's syndrome, and various neurological, dermatological, and systemic autoimmune disorders. Management requires a coordinated multidisciplinary approach focusing on both the underlying thymoma and the specific autoimmune manifestations. Surgical intervention through thymectomy remains a cornerstone of treatment, particularly for myasthenia gravis, where it can lead to significant symptomatic improvement. However, autoimmune conditions may persist or even develop after thymectomy, necessitating disease-specific approaches with systemic immunosuppression. In this review, we discuss the various autoimmune manifestations of thymoma, along with respective information on patient outcomes and treatment strategy. Recent advances in targeted therapies and immunomodulation offer new treatment options, though further research is needed to establish optimal management strategies for this complex patient population.
PMID:40983285 | DOI:10.1016/j.jtho.2025.09.013
Source: https://pubmed.ncbi.nlm.nih.gov/4098328 ... t9+e462414